



## **Dr. Roch Doliveux**

Chief Executive Officer and  
Chairman of the Executive Committee

### **Company statement**

UCB ([www.ucb.com](http://www.ucb.com)) is an innovation-driven global biopharmaceutical company focused on the discovery and development of novel medicines and solutions to transform the lives of people living with severe diseases.

Thanks to a truly patient-centric approach and a strategy focused on two therapeutic areas, immunology and the Central Nervous System, UCB is enjoying a period of sustainable growth, with no major patent expiries within the coming decade. In recent years, the company has brought three innovative drugs to patients across the world: Cimzia<sup>®</sup> (certolizumab pegol) in rheumatoid arthritis and Crohn's disease<sup>1</sup>, Vimpat<sup>®</sup> (lacosamide) in epilepsy and Neupro<sup>®</sup> (rotigotine) in Parkinson's disease and restless legs syndrome.

With research collaborations with eminent universities and third parties, UCB enjoys a rich pipeline of future promising drugs and has built one of the most productive R&D organizations in the industry.

### **Roch Doliveux**

Roch Doliveux has been UCB's Chief Executive Officer and Chairman of the Executive Committee for more than nine years. He joined UCB in October 2003 as Head of UCB's Pharmaceutical business and Deputy Chairman of the Executive Committee. Under his leadership, UCB has developed into a focused patient-centric biopharmaceutical leader recognized for its attractive growth prospects and rich pipeline.

---

<sup>1</sup> \* Cimzia<sup>®</sup>(*certolizumab pegol*) in Crohn's disease is available in Argentina, Brazil, Chili, Mexico, Russia, the US and Switzerland

He is a member of the Board of Directors of UCB, a member of the Board of Stryker Corporation and of the Biotechnology Industry Organization (BIO) both in the US, Vice President on the European Federation of Pharmaceutical Association (EFPIA) Board, Vice-Chairman and member of the Board of the Innovative Medicines Initiative (IMI) which is a public-private partnership between the European Union and EFPIA, as well as a member of the Board of the Vlerick Business school. He also chairs the Caring Entrepreneurship Fund (King Baudouin Foundation), a philanthropic initiative which supports entrepreneurship in health and wellness.

Doctor in Veterinarian Medicine from Maisons-Alfort (France), Roch Doliveux is also Laureate of the Faculty of Medicine, Créteil, and holds an MBA with distinction from INSEAD (France). Roch Doliveux was awarded the Doctor Honoris Causa degree of the University of Liège (Belgium) in October 2011 and was bestowed the title of Commander of the Order of the Crown by the Belgian government in November 2012.

He first joined the pharmaceutical industry with Ciba-Geigy (now Novartis) in Switzerland, Peru and France, and then with Schering-Plough Corporation in various positions in Belgium, France and the US, including President of Schering-Plough International. Before joining UCB, Roch Doliveux was Chief Executive Officer of Pierre Fabre Pharmaceuticals.